REFERENCES
1. Ahn CS, Huang WW. Rosacea pathogenesis. Dermatol Clin. 2018;36(2):81-86.
2. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society expert committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002;46(4):584-587.
3. Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care. Cutis. 2013;92(5):234-40.
4. Alexis AF, Callender VD, Baldwin HE, et al. Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: review and clinical practice experience. J Am Acad Dermatol. 2019 ;80(6):1722-1729.
5. Oussedik E, Boucier M, Tan J. Psychosocial burden and other impacts of rosacea on patient’s quality of life. Dermatol Clin. 2018;36(2):103-113.
6. Harper J, Del Rosso JQ, Ferrusi IL. Cross-sectional survey of the burden of illness of rosacea by erythema severity. J Drugs Dermatol. 2018;17(2):150- 158.
7. Schaller M, Almeida LMC, Bewley A, et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel. Br J Dermatol. 2020;182(5):1269-1276.
8. Del Rosso JQ, Thiboutot D, Gallo R. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. Cutis. 2014;93(3):134-138.
9. Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies. Cutis. 2014;93:18-28.
10. Del Rosso J, Tanghetti E, Webster G, et al. Update on the management of rosacea from the American Acne & Rosacea Society (AARS). J Clin Aesthet Dermatol. 2019;12(6):17-24.
11. McGregor SP, Alinia H, Snyder A, et al. A review of the current modalities for the treatment of papulopustular rosacea. Dermatol Clin. 2018;36(2):135-150.
12. Del Rosso JQ, Sachsman SM. Oral antibiotics in dermatology: a practical overview with clinically relevant correlations and management suggestions. In: Yamauchi PS, Ed. Biologic and systemic agents in dermatology. Springer International Publishing, Cham, Switzerland, 2018:531-539.
13. ORACEA PI
14. SEYSARA PI
15. Moore AY, Charles JEM, Moore S. Sarecycline: a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris. Future Microbiol. 2019;14(14):1235-1242.
16. Moore A, Green LJ, Bruce S, et al. Once-daily oral sarecycline 1.5 mg/kg/ day Is effective for moderate to severe acne vulgaris: results from two identically designed, phase 3, randomized, double-blind clinical trials. J Drugs Dermatol. 2018;17(9):987-996
17. Zhanel G, Critchley I, Lin LY. Microbiological profile of sarecycline, a novel targeted spectrum tetracycline for the treatment of acne vulgaris. Antimicrob Agents Chemother. 2018;63(1):e01297-e1318.
18. Moore AY, Del Rosso J, Johnson JL, et al. Sarecycline: A review of preclinical and clinical evidence. Clin Cosmet Investig Dermatol. 2020;13:553-560.
2. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society expert committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002;46(4):584-587.
3. Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care. Cutis. 2013;92(5):234-40.
4. Alexis AF, Callender VD, Baldwin HE, et al. Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: review and clinical practice experience. J Am Acad Dermatol. 2019 ;80(6):1722-1729.
5. Oussedik E, Boucier M, Tan J. Psychosocial burden and other impacts of rosacea on patient’s quality of life. Dermatol Clin. 2018;36(2):103-113.
6. Harper J, Del Rosso JQ, Ferrusi IL. Cross-sectional survey of the burden of illness of rosacea by erythema severity. J Drugs Dermatol. 2018;17(2):150- 158.
7. Schaller M, Almeida LMC, Bewley A, et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel. Br J Dermatol. 2020;182(5):1269-1276.
8. Del Rosso JQ, Thiboutot D, Gallo R. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. Cutis. 2014;93(3):134-138.
9. Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies. Cutis. 2014;93:18-28.
10. Del Rosso J, Tanghetti E, Webster G, et al. Update on the management of rosacea from the American Acne & Rosacea Society (AARS). J Clin Aesthet Dermatol. 2019;12(6):17-24.
11. McGregor SP, Alinia H, Snyder A, et al. A review of the current modalities for the treatment of papulopustular rosacea. Dermatol Clin. 2018;36(2):135-150.
12. Del Rosso JQ, Sachsman SM. Oral antibiotics in dermatology: a practical overview with clinically relevant correlations and management suggestions. In: Yamauchi PS, Ed. Biologic and systemic agents in dermatology. Springer International Publishing, Cham, Switzerland, 2018:531-539.
13. ORACEA PI
14. SEYSARA PI
15. Moore AY, Charles JEM, Moore S. Sarecycline: a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris. Future Microbiol. 2019;14(14):1235-1242.
16. Moore A, Green LJ, Bruce S, et al. Once-daily oral sarecycline 1.5 mg/kg/ day Is effective for moderate to severe acne vulgaris: results from two identically designed, phase 3, randomized, double-blind clinical trials. J Drugs Dermatol. 2018;17(9):987-996
17. Zhanel G, Critchley I, Lin LY. Microbiological profile of sarecycline, a novel targeted spectrum tetracycline for the treatment of acne vulgaris. Antimicrob Agents Chemother. 2018;63(1):e01297-e1318.
18. Moore AY, Del Rosso J, Johnson JL, et al. Sarecycline: A review of preclinical and clinical evidence. Clin Cosmet Investig Dermatol. 2020;13:553-560.
AUTHOR CORRESPONDENCE
Leon H. Kircik MD wedoderm@yahoo.com
